No Data
(SEC Amendment) Olema Pharmaceuticals(OLMA.US) Director Sells US$17.45 Million in Common Stock
Olema Oncology to Present New Data Combining Palazestrant With Ribociclib at the San Antonio Breast Cancer Symposium
J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)
Express News | Olema Pharmaceuticals Inc : JP Morgan Cuts Target Price to $29 From $31
A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $29 to $30
Optimistic Outlook for Olema Pharmaceuticals: Promising Clinical Data and Strategic Pipeline Developments
President Sean Bohen Sold A Bunch Of Shares In Olema PharmaceuticalsNo Data
No Data
